Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator
This turn valve is considered revolutionary because it supports back-to-back drug infusion through the same device
Approval based on a separate phase III trial among Chinese patients reinforcing mepolizumab’s efficacy and safety data
The Aptivate Champion Run witnessed an enthusiastic participation of over 4,000 Mumbaikars
The workshop was conducted as a part of the NITI–State workshop series
The R&D centre is mainly dedicated to the Process R&D of New Chemical Entities (NCE) development projects
Submission based on positive results from global phase 3 study demonstrating overall survival benefit of TIVDAK over chemotherapy
Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors
The company has secured two orders for male condoms from CMSS worth Rs. 9.65 crores and Rs. 6.58 crores respectively
TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
